Pub Date : 2024-05-02DOI: 10.26442/20751753.2024.1.202593
A. M. Alieva, N. V. Teplova, E. V. Reznik, I. Baykova, Nyurzhanna Kh. Khadzhieva, Kira V. Voronkova, Irina V. Kovtiukh, R. Valiev, I. A. Kotikova, I. G. Nikitin
Chronic heart failure (CHF) is a global medical, social and economic problem. Currently, the search and study of new biomarkers that can provide early diagnosis of CHF, serve as a laboratory tool for assessing the effectiveness of treatment, or be used as prognostic markers and risk stratification criteria are ongoing. Scientists' interest is focused, in particular, on studying the role of fibroblast growth factor 21 (FGF21) in CHF. There is increasing evidence highlighting the value of FGF21 as a new marker for the diagnosis and assessment of prognosis in patients with CHF. The role of FGF21 in CHF is very interesting due to its cardioprotective aspects. Final confirmation of the diagnostic, prognostic and therapeutic roles of FGF21 will come from future studies.
{"title":"Fibroblast growth factor 21 (FGF21): diagnostic, prognostic and therapeutic aspects in heart failure. A review","authors":"A. M. Alieva, N. V. Teplova, E. V. Reznik, I. Baykova, Nyurzhanna Kh. Khadzhieva, Kira V. Voronkova, Irina V. Kovtiukh, R. Valiev, I. A. Kotikova, I. G. Nikitin","doi":"10.26442/20751753.2024.1.202593","DOIUrl":"https://doi.org/10.26442/20751753.2024.1.202593","url":null,"abstract":"Chronic heart failure (CHF) is a global medical, social and economic problem. Currently, the search and study of new biomarkers that can provide early diagnosis of CHF, serve as a laboratory tool for assessing the effectiveness of treatment, or be used as prognostic markers and risk stratification criteria are ongoing. Scientists' interest is focused, in particular, on studying the role of fibroblast growth factor 21 (FGF21) in CHF. There is increasing evidence highlighting the value of FGF21 as a new marker for the diagnosis and assessment of prognosis in patients with CHF. The role of FGF21 in CHF is very interesting due to its cardioprotective aspects. Final confirmation of the diagnostic, prognostic and therapeutic roles of FGF21 will come from future studies.","PeriodicalId":10550,"journal":{"name":"Consilium Medicum","volume":" 18","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141130154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-02DOI: 10.26442/20751753.2024.1.202642
Marina Yu. Zubareva, I. V. Sergienko
Atherosclerosis is a chronic condition that is the main underlying cause of cardiovascular disease. Inflammation is one of the key factors in the pathogenesis of atherosclerosis and its complications. This review explains an up-to-date understanding of the immunological mechanisms of atherogenesis and biomarkers of inflammation, as well as available treatments for low-intensity chronic inflammation. Information is provided on the perspective directions of anti-inflammatory therapy for atherosclerosis being studied.
{"title":"Atherosclerosis and inflammation: Current therapeutic strategies. A review","authors":"Marina Yu. Zubareva, I. V. Sergienko","doi":"10.26442/20751753.2024.1.202642","DOIUrl":"https://doi.org/10.26442/20751753.2024.1.202642","url":null,"abstract":"Atherosclerosis is a chronic condition that is the main underlying cause of cardiovascular disease. Inflammation is one of the key factors in the pathogenesis of atherosclerosis and its complications. This review explains an up-to-date understanding of the immunological mechanisms of atherogenesis and biomarkers of inflammation, as well as available treatments for low-intensity chronic inflammation. Information is provided on the perspective directions of anti-inflammatory therapy for atherosclerosis being studied.","PeriodicalId":10550,"journal":{"name":"Consilium Medicum","volume":" 31","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141129921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-02DOI: 10.26442/20751753.2024.1.202634
E. N. Ievlev, Daria R. Bekhtereva, Zukhra R. Khuzina, Edgar K. Chalgubaev, Irina N. Chekmareva
To date, the problem of rhabdomyolysis remains relevant in Russia. Despite the introduction of modern methods of diagnosis, prevention and treatment, mortality remains high, up to 40%, especially with the addition of acute kidney injury. This article presents a clinical case of rhabdomyolysis, which arose as a result of the combined effects of non-traumatic (toxic effects of methadone, alcohol) and traumatic (vibration and non-physiological position during sleep) factors. This syndrome eventually led to the development of acute kidney damage up to anuria. In this clinical case, intensive infusion and detoxification therapy, including hemodialysis procedures, was carried out, which led to an almost complete restoration of the functional state of the kidneys. Thus, early diagnosis of rhabdomyolysis and AKI based on anamnesis, timely laboratory and instrumental diagnosis can prevent severe kidney damage up to terminal uremia and fatal consequences.
{"title":"Clinical case of mechanical and non-mechanical rhabdomyolysis complicated by acute kidney injury. Case report","authors":"E. N. Ievlev, Daria R. Bekhtereva, Zukhra R. Khuzina, Edgar K. Chalgubaev, Irina N. Chekmareva","doi":"10.26442/20751753.2024.1.202634","DOIUrl":"https://doi.org/10.26442/20751753.2024.1.202634","url":null,"abstract":"To date, the problem of rhabdomyolysis remains relevant in Russia. Despite the introduction of modern methods of diagnosis, prevention and treatment, mortality remains high, up to 40%, especially with the addition of acute kidney injury. This article presents a clinical case of rhabdomyolysis, which arose as a result of the combined effects of non-traumatic (toxic effects of methadone, alcohol) and traumatic (vibration and non-physiological position during sleep) factors. This syndrome eventually led to the development of acute kidney damage up to anuria. In this clinical case, intensive infusion and detoxification therapy, including hemodialysis procedures, was carried out, which led to an almost complete restoration of the functional state of the kidneys. Thus, early diagnosis of rhabdomyolysis and AKI based on anamnesis, timely laboratory and instrumental diagnosis can prevent severe kidney damage up to terminal uremia and fatal consequences.","PeriodicalId":10550,"journal":{"name":"Consilium Medicum","volume":" 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141129876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-02DOI: 10.26442/20751753.2024.1.202665
K. Zherebchikova, D. S. Bubnov, A. Ermolaeva, Madina O. Soltakhanova, Y. P. Sych, M. Ezhov, Valentin V. Fadeev
Atrial fibrillation is the most common heart rhythm disorder in patients with chronic heart failure. One of the most effective antiarrhythmic drugs for the treatment and prevention of a wide range of supraventricular and ventricular tachyarrhythmia is amiodarone. In the group of patients with paroxysmal atrial fibrillation and low left ventricular ejection fraction, it is the drug of choice when conducting a „rhythm control“ strategy. Patients receiving amiodarone often develop an adverse event – amiodarone-induced thyrotoxicosis, which exacerbates the course of cardiovascular pathology. In this article, we consider a clinical case of amiodarone-induced thyrotoxicosis in a 30-year-old patient with dilated cardiomyopathy and agranulocytosis that developed against the background of thyrostatic therapy.
{"title":"Differential diagnosis of amiodarone-induced thyrotoxicosis in a patient with atrial fibrillation and agranulocytosis on the background of thyrostatic therapy. Case report","authors":"K. Zherebchikova, D. S. Bubnov, A. Ermolaeva, Madina O. Soltakhanova, Y. P. Sych, M. Ezhov, Valentin V. Fadeev","doi":"10.26442/20751753.2024.1.202665","DOIUrl":"https://doi.org/10.26442/20751753.2024.1.202665","url":null,"abstract":"Atrial fibrillation is the most common heart rhythm disorder in patients with chronic heart failure. One of the most effective antiarrhythmic drugs for the treatment and prevention of a wide range of supraventricular and ventricular tachyarrhythmia is amiodarone. In the group of patients with paroxysmal atrial fibrillation and low left ventricular ejection fraction, it is the drug of choice when conducting a „rhythm control“ strategy. Patients receiving amiodarone often develop an adverse event – amiodarone-induced thyrotoxicosis, which exacerbates the course of cardiovascular pathology. In this article, we consider a clinical case of amiodarone-induced thyrotoxicosis in a 30-year-old patient with dilated cardiomyopathy and agranulocytosis that developed against the background of thyrostatic therapy.","PeriodicalId":10550,"journal":{"name":"Consilium Medicum","volume":" 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141129944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-02DOI: 10.26442/20751753.2024.1.202586
A. I. Analeev, S. P. Semitko, I. E. Chernysheva, Nikita V. Belikov, I. V. Khaydukova, A. Borde, D. G. Ioseliani, P. S. Timashev, V. V. Fomin
The first use of ultrasound in treating vascular disorders dates back to 1976. Since then, numerous original studies have been published, offering various concepts of its use. Many technical solutions have been developed and used with variable success, some of which have been developed in modern medicine. This article discusses the development of ultrasound therapeutic technologies in treating vascular disorders. The history of methods is described, available data on promising future areas are presented, and information on existing methods and devices is given.
{"title":"Ultrasound-assisted intravascular therapy: history and future perspectives of development. A review","authors":"A. I. Analeev, S. P. Semitko, I. E. Chernysheva, Nikita V. Belikov, I. V. Khaydukova, A. Borde, D. G. Ioseliani, P. S. Timashev, V. V. Fomin","doi":"10.26442/20751753.2024.1.202586","DOIUrl":"https://doi.org/10.26442/20751753.2024.1.202586","url":null,"abstract":"The first use of ultrasound in treating vascular disorders dates back to 1976. Since then, numerous original studies have been published, offering various concepts of its use. Many technical solutions have been developed and used with variable success, some of which have been developed in modern medicine. This article discusses the development of ultrasound therapeutic technologies in treating vascular disorders. The history of methods is described, available data on promising future areas are presented, and information on existing methods and devices is given.","PeriodicalId":10550,"journal":{"name":"Consilium Medicum","volume":" 31","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141130019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-02DOI: 10.26442/20751753.2024.1.202591
Laura H. Sarieva, S. Nasonova, I. V. Zhirov, Irina A. Zhirova, S. N. Tereshchenko
The relevance and importance of the problem of acute decompensation of heart failure for the health care system not only in Russia, but also in the whole world is caused by a significant increase in the number of hospitalizations, associated increase in financial costs and extremely unfavorable prognosis in this group of patients. The article is devoted to the pathogenesis of acute decompensation of heart failure and the place of asymptomatic hyperuricemia in the development of this condition. Hyperuricemia is considered as a prognostic marker of unfavorable prognosis in patients with both cardiovascular diseases in general and acute decompensation of heart failure in particular. Special emphasis is made on approaches to drug therapy, tactics of xanthine oxidase inhibitor allopurinol use, doses are analyzed in terms of efficacy, influence on prognosis, methods of achieving and controlling target values of hyperuricemia are discussed.
{"title":"Hyperuricemia and acute decompensation of heart failure: is there a causative link? A review","authors":"Laura H. Sarieva, S. Nasonova, I. V. Zhirov, Irina A. Zhirova, S. N. Tereshchenko","doi":"10.26442/20751753.2024.1.202591","DOIUrl":"https://doi.org/10.26442/20751753.2024.1.202591","url":null,"abstract":"The relevance and importance of the problem of acute decompensation of heart failure for the health care system not only in Russia, but also in the whole world is caused by a significant increase in the number of hospitalizations, associated increase in financial costs and extremely unfavorable prognosis in this group of patients. The article is devoted to the pathogenesis of acute decompensation of heart failure and the place of asymptomatic hyperuricemia in the development of this condition. Hyperuricemia is considered as a prognostic marker of unfavorable prognosis in patients with both cardiovascular diseases in general and acute decompensation of heart failure in particular. Special emphasis is made on approaches to drug therapy, tactics of xanthine oxidase inhibitor allopurinol use, doses are analyzed in terms of efficacy, influence on prognosis, methods of achieving and controlling target values of hyperuricemia are discussed.","PeriodicalId":10550,"journal":{"name":"Consilium Medicum","volume":" 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141129891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-02DOI: 10.26442/20751753.2024.1.202738
A. M. Makarevich, A. Zaytsev, E. M. Makarevich, Hasan A. Akhmedkhanov
Pulmonary sequestration (PS) is a rare congenital malformation of the lungs referring to an abnormal (non-functioning) segment of the lung that has no connection with the tracheobronchial tree, which receives arterial blood from systemic circulation and has various types of venous outflow. PS is divided into intralobar (intrapulmonary) and extralobar (extrapulmonary) types. The distinctive feature of extralobar pulmonary sequestration is the presence of its own visceral pleura. PS is most common in pediatric practice; in some cases, this disease may remain oligosymptomatic or asymptomatic in children and adolescents. Adults with PS have a higher risk of recurrent pneumonia, chest pain, and episodes of hemoptysis. Cases of the late onset of PS are reported in a few foreign and Russian publications. The special feature was the elderly patients with a long asymptomatic course of PS, "pseudopneumonic" clinical onset, episodes of thoracalgia and hemoptysis. We present a case of an adult male soldier with PS clinically simulated a respiratory infection in the lower lobe of the left lung with severe pain and hemoptysis. In addition, the patient has a concomitant congenital heart defect.
{"title":"Extralobar pulmonary sequestration in an adult male with a heart defect. Case report","authors":"A. M. Makarevich, A. Zaytsev, E. M. Makarevich, Hasan A. Akhmedkhanov","doi":"10.26442/20751753.2024.1.202738","DOIUrl":"https://doi.org/10.26442/20751753.2024.1.202738","url":null,"abstract":"Pulmonary sequestration (PS) is a rare congenital malformation of the lungs referring to an abnormal (non-functioning) segment of the lung that has no connection with the tracheobronchial tree, which receives arterial blood from systemic circulation and has various types of venous outflow. PS is divided into intralobar (intrapulmonary) and extralobar (extrapulmonary) types. The distinctive feature of extralobar pulmonary sequestration is the presence of its own visceral pleura. PS is most common in pediatric practice; in some cases, this disease may remain oligosymptomatic or asymptomatic in children and adolescents. Adults with PS have a higher risk of recurrent pneumonia, chest pain, and episodes of hemoptysis. Cases of the late onset of PS are reported in a few foreign and Russian publications. The special feature was the elderly patients with a long asymptomatic course of PS, \"pseudopneumonic\" clinical onset, episodes of thoracalgia and hemoptysis. We present a case of an adult male soldier with PS clinically simulated a respiratory infection in the lower lobe of the left lung with severe pain and hemoptysis. In addition, the patient has a concomitant congenital heart defect.","PeriodicalId":10550,"journal":{"name":"Consilium Medicum","volume":" 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141129915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-02DOI: 10.26442/20751753.2024.1.202777
V. V. Fomin
Iron supplements and/or blood transfusions in combination with recombinant human erythropoietin injections are routinely used to correct renal anemia, which is a common complication of end-stage renal disease. However, massive blood transfusions and inadequate intravenous iron supplementation can lead to iron overload syndrome, and anemia is not always nephrogenic. A rare clinical case of a patient with end-stage chronic kidney disease with complex genesis of anemia, who is on hemodialysis, is presented. The case is interesting because the prescription of first-line drugs was life-threatening in nature, and sevelamer was the drug chosen for the correction of mineral-bone disorders.
{"title":"Correction of hyperphosphatemia in a patient with end-stage chronic kidney disease and a complex case of anemia. A clinical case","authors":"V. V. Fomin","doi":"10.26442/20751753.2024.1.202777","DOIUrl":"https://doi.org/10.26442/20751753.2024.1.202777","url":null,"abstract":"Iron supplements and/or blood transfusions in combination with recombinant human erythropoietin injections are routinely used to correct renal anemia, which is a common complication of end-stage renal disease. However, massive blood transfusions and inadequate intravenous iron supplementation can lead to iron overload syndrome, and anemia is not always nephrogenic. A rare clinical case of a patient with end-stage chronic kidney disease with complex genesis of anemia, who is on hemodialysis, is presented. The case is interesting because the prescription of first-line drugs was life-threatening in nature, and sevelamer was the drug chosen for the correction of mineral-bone disorders.","PeriodicalId":10550,"journal":{"name":"Consilium Medicum","volume":" 24","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141130082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-02DOI: 10.26442/20751753.2024.1.202532
D. Trukhan, Sergej N. Filimonov
Proton pump inhibitors (PPIs) are the most effective drugs for treating acid-related diseases. In recent decades, the use of PPIs has increased exponentially. From gastroenterological practice, PPIs are being actively introduced into other specialties, in particular in cardiology and rheumatology, where they are used to protect the mucous membrane of the gastrointestinal tract and prevent gastrointestinal bleeding during long-term antithrombotic therapy and long-term use of non-steroidal anti-inflammatory drugs. For a long time, PPIs were considered completely safe drugs for both short-term and long-term use. However, modern clinical guidelines note that when prescribing PPIs in large doses for a long period, the possibility of side effects should be taken into account. In recent years, a number of foreign reviews have been published that examine the relationship between PPIs and a number of diseases/conditions, including the question of a possible association of PPI use with an increased risk of cardiovascular complications, but note the inconsistency of these data. We searched the PubMed and Scopus information databases for publications on the safety of PPI use, including sources up to 12/01/2023. In this review, we examined the possible cardiovascular risk of long-term use of PPIs. Analysis of publications, despite a number of contradictions, allows us to conclude that the cardiovascular risk with long-term use of PPIs is real and must be taken into account when prescribing PPIs for a long period and to comorbid/multimorbid patients.
质子泵抑制剂（PPI）是治疗胃酸相关疾病的最有效药物。近几十年来，PPIs 的使用量成倍增长。从胃肠病学实践开始，PPIs 正被积极引入其他专科，特别是心脏病学和风湿病学，用于在长期抗血栓治疗和长期使用非甾体抗炎药物期间保护胃肠道粘膜和防止胃肠道出血。长期以来，PPIs 被认为是短期和长期使用都完全安全的药物。然而，现代临床指南指出，在长期大剂量处方 PPIs 时，应考虑到副作用的可能性。近年来，国外发表了一些综述，研究了 PPI 与多种疾病/病症之间的关系，包括 PPI 的使用可能与心血管并发症风险增加有关的问题，但也注意到了这些数据的不一致性。我们在 PubMed 和 Scopus 信息数据库中检索了截至 2023 年 1 月 12 日有关 PPI 使用安全性的出版物。在这篇综述中，我们研究了长期使用 PPIs 可能带来的心血管风险。尽管存在一些矛盾之处，但通过对出版物的分析，我们得出结论：长期使用 PPIs 确实存在心血管风险，因此在长期处方 PPIs 和为合并症/多发病患者处方时必须考虑到这一点。
{"title":"Cardiovascular risk with long-term use of proton pump inhibitors: myth or reality. A review","authors":"D. Trukhan, Sergej N. Filimonov","doi":"10.26442/20751753.2024.1.202532","DOIUrl":"https://doi.org/10.26442/20751753.2024.1.202532","url":null,"abstract":"Proton pump inhibitors (PPIs) are the most effective drugs for treating acid-related diseases. In recent decades, the use of PPIs has increased exponentially. From gastroenterological practice, PPIs are being actively introduced into other specialties, in particular in cardiology and rheumatology, where they are used to protect the mucous membrane of the gastrointestinal tract and prevent gastrointestinal bleeding during long-term antithrombotic therapy and long-term use of non-steroidal anti-inflammatory drugs. For a long time, PPIs were considered completely safe drugs for both short-term and long-term use. However, modern clinical guidelines note that when prescribing PPIs in large doses for a long period, the possibility of side effects should be taken into account. In recent years, a number of foreign reviews have been published that examine the relationship between PPIs and a number of diseases/conditions, including the question of a possible association of PPI use with an increased risk of cardiovascular complications, but note the inconsistency of these data. We searched the PubMed and Scopus information databases for publications on the safety of PPI use, including sources up to 12/01/2023. In this review, we examined the possible cardiovascular risk of long-term use of PPIs. Analysis of publications, despite a number of contradictions, allows us to conclude that the cardiovascular risk with long-term use of PPIs is real and must be taken into account when prescribing PPIs for a long period and to comorbid/multimorbid patients.","PeriodicalId":10550,"journal":{"name":"Consilium Medicum","volume":" 26","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141129991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-02DOI: 10.26442/20751753.2024.1.202601
L. Salyamova, Ksenia I. Pavlenko, A. Khromova, V. Oleynikov
Background. Despite the global trend towards a decrease in mortality from cardiovascular pathology of atherosclerotic genesis, this group of diseases continues to occupy a leading position in the structure of disability and mortality among the population of many countries. Aim. Identification of noninvasive markers of arterial wall lesions associated with the presence of arterial hypertension (AH) and coronary heart disease (CHD) in persons younger than 55 years. Materials and methods. The study included 81 people. Three groups were distinguished from them: 1st (n=31) – a control group of practically healthy individuals, average age – 43 (40; 48) years; 2nd group (n=21) – patients with coronary heart disease without a history of cardiovascular diseases (CVD), average age – 45,5±6,1; group 3 (n=29) – patients with AH without CHD, average age – 47 (35; 50) years. The parameters of a biochemical blood test were determined, volumetric sphygmography and a sample with post-occlusive reactive hyperemia were performed. Results. In groups of patients with CHD and AH, negative changes in the lipid profile and higher glucose levels were recorded compared to healthy individuals. According to the results of volumetric sphygmography, the pulse wave velocity in arteries of predominantly elastic type (R/L-PWV) in group 1 was 10.1±1.7 m/s, in group 2 – 12.9±1.8 m/s, in group 3 – 13.1 (12; 14) m/s (р1–2=0.029; р1–30.001); cardio-ankle vascular index (CAVI) – 6.5±0.7, 7.7 (7; 8.7) and 7.8 (7.3; 8.4), respectively (р1–20.001; р1–30.001). According to the data of the test with post-occlusive reactive hyperemia, a comparably high frequency of pathological values of flow-dependent vasodilation (FDV) and reactivity index (RI) was demonstrated in patients with CHD and AH (р1–20.05; р1–30.05). A multifactorial model of noninvasive diagnosis of CHD in individuals without a history of CVD, including non-high-density lipoprotein cholesterol, R/L-PWV, and FDV, has been developed. For patients with AH, glucose, lipid metabolism, R/L-PWV, pulse wave velocity in muscle-type arteries (B-PWV), augmentation index (AI), biological age, CAVI, FDV, RI were the risk factors for the presence of the disease in the anamnesis. Conclusion. The results obtained confirm the importance of an integrated approach in the screening diagnosis of CVD.
{"title":"Possibilities of noninvasive diagnostics of cardiovascular diseases associated with atherosclerosis","authors":"L. Salyamova, Ksenia I. Pavlenko, A. Khromova, V. Oleynikov","doi":"10.26442/20751753.2024.1.202601","DOIUrl":"https://doi.org/10.26442/20751753.2024.1.202601","url":null,"abstract":"Background. Despite the global trend towards a decrease in mortality from cardiovascular pathology of atherosclerotic genesis, this group of diseases continues to occupy a leading position in the structure of disability and mortality among the population of many countries. \u0000Aim. Identification of noninvasive markers of arterial wall lesions associated with the presence of arterial hypertension (AH) and coronary heart disease (CHD) in persons younger than 55 years. \u0000Materials and methods. The study included 81 people. Three groups were distinguished from them: 1st (n=31) – a control group of practically healthy individuals, average age – 43 (40; 48) years; 2nd group (n=21) – patients with coronary heart disease without a history of cardiovascular diseases (CVD), average age – 45,5±6,1; group 3 (n=29) – patients with AH without CHD, average age – 47 (35; 50) years. The parameters of a biochemical blood test were determined, volumetric sphygmography and a sample with post-occlusive reactive hyperemia were performed. \u0000Results. In groups of patients with CHD and AH, negative changes in the lipid profile and higher glucose levels were recorded compared to healthy individuals. According to the results of volumetric sphygmography, the pulse wave velocity in arteries of predominantly elastic type (R/L-PWV) in group 1 was 10.1±1.7 m/s, in group 2 – 12.9±1.8 m/s, in group 3 – 13.1 (12; 14) m/s (р1–2=0.029; р1–30.001); cardio-ankle vascular index (CAVI) – 6.5±0.7, 7.7 (7; 8.7) and 7.8 (7.3; 8.4), respectively (р1–20.001; р1–30.001). According to the data of the test with post-occlusive reactive hyperemia, a comparably high frequency of pathological values of flow-dependent vasodilation (FDV) and reactivity index (RI) was demonstrated in patients with CHD and AH (р1–20.05; р1–30.05). A multifactorial model of noninvasive diagnosis of CHD in individuals without a history of CVD, including non-high-density lipoprotein cholesterol, R/L-PWV, and FDV, has been developed. For patients with AH, glucose, lipid metabolism, R/L-PWV, pulse wave velocity in muscle-type arteries (B-PWV), augmentation index (AI), biological age, CAVI, FDV, RI were the risk factors for the presence of the disease in the anamnesis. \u0000Conclusion. The results obtained confirm the importance of an integrated approach in the screening diagnosis of CVD.","PeriodicalId":10550,"journal":{"name":"Consilium Medicum","volume":" 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141129874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：